Systemic active immunotherapy is shifting from the middle ages to a renaissance period G. MathéL. Olsson Editorial Pages: 197 - 199
The effects of Muramyldipeptide (MDP) in cell-mediated immunity A. Matter Original Articles Pages: 201 - 210
Circulating immune complexes as possible cause for anticomplementary activity in humans with malignant melanoma R. K. GuptaA. N. TheofilopoulosD. L. Morton Original Articles Pages: 211 - 221
Immunotherapy of lung cancer with Corynebacterium parvum Houshang MoayeriHiroshi TakitaJ. E. Sokal Original Articles Pages: 223 - 226
Prognostic significance of cell surface phenotype in adult acute lymphoblastic leukaemia T. A. ListerM. M. RobertsM. F. Greaves Original Articles Pages: 227 - 230
A phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma M. J. MastrangeloR. E. BelletD. Berd Original Articles Pages: 231 - 236
Influence of BM 12.531 (Prop. INN azimexon) on the lymphocyte transformation and the percentage of active T lymphocytes in vivo and in vitro in man D. BoernerU. BickerH. J. Peters Original Articles Pages: 237 - 242
Immunotherapy of osteogenic sarcoma with transfer factor Vera S. ByersL. LeCamAdeline J. Hackett Original Articles Pages: 243 - 253
Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants R. C. ButlerA. Nowotny Original Articles Pages: 255 - 262
Agranulocytosis and tumoural facilitation induced by levamisole in a case of IgG multiple myeloma C. Focan Letter To The Editor Pages: 263 - 264
